Personalis, Inc. — Investor Relations & Filings

Personalis, Inc. is a company specializing in advanced cancer genomics that provides sequencing and data analysis solutions to transform the active management of cancer. The company's core technology is the NeXT Platform, which supports a suite of advanced genomic tests. Key offerings include NeXT Personal®, an ultra-sensitive, personalized liquid biopsy test for detecting molecular residual disease (MRD) and cancer recurrence earlier than standard imaging. The company also offers NeXT Dx™, a comprehensive tumor profiling service that analyzes the exome to help guide targeted therapy decisions. For its biopharmaceutical partners, Personalis provides the ImmunoID NeXT® platform, a biomarker analysis tool that supports the development of personalized cancer therapies and vaccines. By combining deep genomic sequencing with advanced analytics, Personalis aims to provide critical insights for clinicians and researchers to enable personalized treatment strategies.